Objective To compare the efficacy and safety between gemcitabine (GEM)and epirubicin (EPI)in intravesical instillation for preventing postoperative recurrence of non-muscle-in-vasive bladder cancer. Methods From June 2015 to June 2016,80 cases of non-muscle-invasive bladder cancer were treated with transurethral resection of bladder tumor (TURBT),then GEM and EPI were used in intravesical instillation respectively.The recurrence of two groups and adverse reac-tions were observed during the follow-up period of one to two years. Results The recurrence rate was 20.0% in the GEM group and the recurrence rate was 22.5% in the EPI group.There was no significant difference in the recurrence rate between the two groups (P >0.05).The incidence of ad-verse reactions was 12.5% in the GEM group and the incidence of adverse reactions in the EPI group was 32.5%.The incidence of adverse reactions in GEM group was significantly lower than that in EPI group (χ2 =4.621,P <0.05). Conclusions GEM and EPI have similar effects on the preven-tion of recurrence of bladder cancer,while GEM has less adverse reactions.Thus,the patient is well tolerated with GEM,and it's worthy of clinical use.%目的 探讨吉西他滨(GEM)与表柔比星(EPI)膀胱灌注预防非肌层浸润性膀胱癌术后复发的疗效及其安全性.方法 2015年6月至2016年6月收治的非肌层浸润性膀胱癌患者80例纳入研究,全部患者于经尿道膀胱肿瘤电切术(transurethral resection of bladder tumor,TURBT)后随机分别予以GEM和EPI膀胱灌注治疗.随访1~2年,观察两组的复发情况及不良反应.结果 GEM组2年内复发率为20.0%,EPI组2年内复发率为22.5%,两组复发率比较差异无统计学意义(P>0.05);两组不良反应发生率分别为12.5%(GEM组)和32.5%(EPI组),GEM组不良反应发生率明显低于EPI组(χ2=4.621,P<0.05).结论 GEM和EPI预防膀胱癌术后复发效果相近,而GEM膀胱灌注不良反应更少,患者耐受性好,值得临床推广应用.
展开▼